Literature DB >> 23474635

131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.

S G DuBois1, K K Matthay.   

Abstract

Neuroblastoma is an aggressive childhood cancer, with a propensity for early widespread metastasis. Approximately 90% of tumors accumulate the norepinephrine analogue metaiodobenzylguanidine (MIBG) avidly, allowing the use of radiolabeled MIBG for targeted imaging and radiotherapy. After preclinical studies demonstrated activity of 131I-MIBG in models of neuroblastoma, clinical development of this agent ensued. Early clinical trials of 131I-MIBG in patients with relapsed or refractory neuroblastoma defined the toxicity profile of this agent, with myelosuppression as the main dose-limiting toxicity. Subsequent trials defined the activity of 131I-MIBG, with response rates of 20-40% in patients with relapsed or refractory disease. More recent clinical trials have tested 131I-MIBG in combination with chemotherapy or as a component of myeloablative therapies. Given the documented activity of 131I-MIBG, future studies will need to evaluate the impact of radiation sensitizers on this activity and define the role of this agent in treating patients with newly diagnosed high-risk neuroblastoma.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23474635

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN： 1824-4785            Impact factor:   2.346


  8 in total

1.  Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.

Authors:  Shih-ying Huang; Wesley E Bolch; Choonsik Lee; Henry F Van Brocklin; Miguel H Pampaloni; Randall A Hawkins; Aimee Sznewajs; Steven G DuBois; Katherine K Matthay; Youngho Seo
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

2.  Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide.

Authors:  David A Edmondson; Erin E Karski; Ayano Kohlgruber; Harsha Koneru; Katherine K Matthay; Shelly Allen; Christine L Hartmann; Leif E Peterson; Steven G DuBois; Matthew A Coleman
Journal:  Radiat Res       Date:  2016-08-24       Impact factor: 2.841

3.  Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures.

Authors:  Angela C Evans; Tim Setzkorn; David A Edmondson; Haley Segelke; Paul F Wilson; Katherine K Matthay; M Meaghan Granger; Araz Marachelian; Daphne A Haas-Kogan; Steven G DuBois; Matthew A Coleman
Journal:  Radiat Res       Date:  2022-02-01       Impact factor: 2.841

4.  A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment.

Authors:  Kween Saimuang; Khomson Suttisintong; Narongpol Kaewchangwat; Eknarin Thanayupong; Yodsathorn Wongngam; Putthiporn Charoenphun; Rujira Wanotayan; Abdelhamid Elaissari; Suradej Hongeng; Duangporn Polpanich; Kulachart Jangpatarapongsa
Journal:  RSC Adv       Date:  2021-07-20       Impact factor: 4.036

5.  Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

Authors:  Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay
Journal:  Eur J Cancer       Date:  2016-08-27       Impact factor: 9.162

6.  Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).

Authors:  Margaret J Zhou; Michelle Y Doral; Steven G DuBois; Judith G Villablanca; Gregory A Yanik; Katherine K Matthay
Journal:  Eur J Cancer       Date:  2015-08-05       Impact factor: 9.162

7.  A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.

Authors:  Brian D Weiss; Gregory Yanik; Arlene Naranjo; Fan F Zhang; Wendy Fitzgerald; Barry L Shulkin; Marguerite T Parisi; Heidi Russell; Stephan Grupp; Luke Pater; Peter Mattei; Yael Mosse; Hollie A Lai; Jason A Jarzembowski; Hiroyuki Shimada; Judith G Villablanca; Roger Giller; Rochelle Bagatell; Julie R Park; Katherine K Matthay
Journal:  Pediatr Blood Cancer       Date:  2021-05-24       Impact factor: 3.838

8.  Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.

Authors:  Ji Won Lee; Sanghoon Lee; Hee Won Cho; Youngeun Ma; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Eun Joo Cho; Suk-Koo Lee; Do Hoon Lim
Journal:  J Hematol Oncol       Date:  2017-05-16       Impact factor: 17.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.